Literature DB >> 23942873

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.

Dominique Frechette1, Lise Paquet, Shailendra Verma, Mark Clemons, Paul Wheatley-Price, Stan Z Gertler, Xinni Song, Nadine Graham, Susan Dent.   

Abstract

The goal of this project was to investigate the contentious issue of a possible effect of endocrine therapy (ET) on sexual dysfunction (SD) in postmenopausal early stage breast cancer survivors. To date, few studies have assessed sexual functioning prior to initiating ET and none have taken sexual distress into account when reporting the prevalence of ET-induced SD. We report the findings of a study on the change in SD (defined as experiencing sexual problems causing distress) during the first 6 months of ET usage. Between January 2009 and May 2011, 118 patients entered the study and 66 completed questionnaires prior to initiation of ET and after 6 months of use. Sexual functioning (SF) was evaluated with the female sexual function index while sexual distress was assessed with the female sexual distress scale (FSDS-R). Gynecological symptoms were measured with the FACT-B ES subscale. Over time, the level of gynecological symptoms increased (p < 0.001), whereas no decline in SF was observed. The percentage of women who reported experiencing at least one sexual problem (85 %) and the percentage who were sexually distressed (30 %) remained the same across time. Importantly, the change in the prevalence of SD between baseline (24 %) and 6 months (29 %) was not statistically significant. Women experiencing SD at baseline were more likely to experience SD after 6 months of ET usage (OR = 7.4, 95 % CI = 1.5-36.9) than women who had no SD prior to initiating ET. The observation that SF remained stable across time is encouraging news. However, longer follow-up and the inclusion of women who were premenopausal at diagnosis are needed to determine the potential influence of extended duration of ET (e.g., at least 5 years) on SD. Further studies, including assessing the impact of early identification of patients at risk of developing SD and timely intervention, are warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942873     DOI: 10.1007/s10549-013-2659-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients.

Authors:  Leticia Aptecar; Frederic Fiteni; Marta Jarlier; Stephanie Delaine; Violaine Guillerme; William Jacot; Veronique D'Hondt
Journal:  Breast Cancer Res Treat       Date:  2021-01-15       Impact factor: 4.872

Review 2.  Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.

Authors:  A A Joy; M Ghosh; R Fernandes; M J Clemons
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

3.  Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.

Authors:  Leslie R Schover; George P Baum; Lisa A Fuson; Abenaa Brewster; Amal Melhem-Bertrandt
Journal:  J Sex Med       Date:  2014-08-21       Impact factor: 3.802

4.  Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review.

Authors:  Yehui Zhu; Susan M Cohen; Margaret Q Rosenzweig; Catherine M Bender
Journal:  Cancer Nurs       Date:  2019 Sep/Oct       Impact factor: 2.592

5.  Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.

Authors:  Suzanne N Landi; Kemi M Doll; Jeannette T Bensen; Laura Hendrix; Carey K Anders; Jennifer M Wu; Hazel B Nichols
Journal:  Cancer Causes Control       Date:  2016-09-28       Impact factor: 2.506

6.  Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors.

Authors:  Sharon L Bober; E Fine; C J Recklitis
Journal:  J Cancer Surviv       Date:  2019-09-03       Impact factor: 4.442

Review 7.  Sexual health as a survivorship issue for female cancer survivors.

Authors:  Don S Dizon; Daphne Suzin; Susanne McIlvenna
Journal:  Oncologist       Date:  2014-01-06

8.  Adapting a couple-based intimacy enhancement intervention to breast cancer: A developmental study.

Authors:  Jennifer Barsky Reese; Laura S Porter; Kristen E Casale; Elissa T Bantug; Sharon L Bober; Sharon C Schwartz; Katherine Clegg Smith
Journal:  Health Psychol       Date:  2016-08-15       Impact factor: 4.267

9.  Talking about sexual health during survivorship: understanding what shapes breast cancer survivors' willingness to communicate with providers.

Authors:  Mollie Rose Canzona; Carla L Fisher; Kevin B Wright; Christy J W Ledford
Journal:  J Cancer Surviv       Date:  2019-11-18       Impact factor: 4.442

10.  Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.

Authors:  Sharon L Bober; Christopher J Recklitis; Alexis L Michaud; Alexi A Wright
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.